Dr. Haut was Chief Business Officer of AskBio, where he led the firm’s business development activities and spearheaded AskBio’s $4 billion acquisition by Bayer AG. In a career spanning academic science, consulting, sales management, and business development, he has completed transactions exceeding $8 billion and been instrumental in multiple product launches. He has also served on the boards of several healthcare companies, including firms involved in joint replacement and repair. Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, and The Medicines Company. More recently, he was Chief Business Officer of Histogenics and Sherlock Biosciences. He earned his PhD in Molecular Biology from the Medical School at the University of Missouri-Columbia and an MBA from Washington University’s Olin School of Business.

Dr. Robblee brings over 15 years of development experience to the Chemistry, Manufacturing, and Controls (CMC) function at Carmine. At the exosome therapeutics company Codiak BioSciences, he led the Analytical Development team and played a leading Regulatory and CMC role in the successful IND/IMPD submissions of their first clinical products exoSTING and exoIL-12. Before leading the Analytical Development team at the non-viral gene therapy company Generation Bio, he spent over a decade at Momenta Pharmaceuticals in the Analytical Research, Analytical Development, and CMC Regulatory groups on the analytical and regulatory framework for most of their biosimilar products, including biosimilar versions of Humira®, Orencia®, and Eylea®. Dr. Robblee received his Ph.D. from the University of California, Berkeley in biophysical chemistry, and completed his postdoctoral training in the biochemistry department of the Massachusetts Institute of Technology.

Qin has over 15 years of drug discovery and development experience. She previously was the Senior Director of Viral Therapeutics at Ascidian Therapeutics and the Director of Platform Technology at Rubius Therapeutics. Qin brings her extensive R&D experience with gene therapy vectors and red blood cell-based therapy to Carmine. She most recently served as the Senior Director at Ascidian Therapeutics, leading the in vitro and in vivo Proof of Concept research for a novel gene therapy platform. Prior to that Qin was the Director of Platform Technology at Rubius Therapeutics, building the team from the ground up and leading the Red Cell Therapeutics platform and early programs to successful IND submissions. Qin’s industry career started on leading antiviral drug discovery teams and projects at a biotech and later at Novartis and AstraZeneca. She received her Ph.D. in Microbiology from the University of Alabama at Birmingham. Her postdoctoral training was completed at the Salk Institute for Biological Studies.

Tenzin obtained his Ph.D. in Molecular Pharmacology from New York University Medical Center. During his Ph.D., he studied the effect of perturbation of cell signaling pathways in the context of cancer and embryonic stem cells. Tenzin has co-authored 5 publications and one book chapter in the fields of RNAi and small molecule and small-biologic screening. After his Ph.D., Tenzin did a short postdoctoral stint at the Genome Institute of Singapore, in collaboration with an industrial partner on discovering small-biologics against immunomodulating receptors. Tenzin is a Fulbright Scholar and recipient of several graduate fellowships.

Dr. Alkan's passion and interest in gene therapy started 20 years ago while working in Germany's first gene therapy group and trial. His Ph.D. studies focusing on non-and viral gene therapy vectors were a close collaboration between the University of Freiburg in Germany and M.I.T. He was a visiting student in Philip Leboulch's lab, the scientific founder of the company Bluebird. He continued his training as a PostDoc in Helen Blau's lab at Stanford University in the field of Stem Cell Biology. His subsequent career steps brought him to the Broad Institute of Harvard and M.I.T. as a group leader, followed by a industry-based group leader position in a mid-size Cambridge-based biotech company Merrimack Pharmaceuticals. There, he extended his knowledge in virology and alternative delivery moieties, using liposomal nanoparticles (LNP) to deliver nucleic acids, such as plasmid and small interfering RNAs. His interest and dedication towards the optimization of non-viral gene therapy platforms and technologies were further enhanced by joining a start-up in Cambridge where he helped building re-dosable and titratable gene therapy platforms based on linear close-end DNA species. Shortly before joining Carmine, Ozan focused on establishing and developing RNA-based LNP delivery platforms and reprogramming T-Cells invivo at Tidal Therapeutics.